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Abstract
Objective
To identify the genetic and physiologic basis for recessive myasthenic congenital myopathy in 2
families, suggestive of a channelopathy involving the sodium channel gene, SCN4A.
Methods
A combination of whole exome sequencing and targeted mutation analysis, followed by voltage-
clamp studies of mutant sodium channels expressed in ﬁbroblasts (HEK cells) and Xenopus
oocytes.
Results
Missense mutations of the same residue in the skeletal muscle sodium channel, R1460 of
NaV1.4, were identiﬁed in a family and a single patient of Finnish origin (p.R1460Q) and
a proband in the United States (p.R1460W). Congenital hypotonia, breathing diﬃculties,
bulbar weakness, and fatigability had recessive inheritance (homozygous p.R1460W or com-
pound heterozygous p.R1460Q and p.R1059X), whereas carriers were either asymptomatic
(p.R1460W) or had myotonia (p.R1460Q). Sodium currents conducted by mutant channels
showed unusual mixed defects with both loss-of-function (reduced amplitude, hyperpolarized
shift of inactivation) and gain-of-function (slower entry and faster recovery from inactivation)
changes.
Conclusions
Novel mutations in families with myasthenic congenital myopathy have been identiﬁed at
p.R1460 of the sodium channel. Recessive inheritance, with experimentally established loss-of-
function, is a consistent feature of sodium channel based myasthenia, whereas the mixed gain of
function for p.R1460 may also cause susceptibility to myotonia.
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Several allelic disorders of skeletal muscle are caused by
mutations of SCN4A that encodes the pore-forming α subunit
of the voltage-gated sodium channel (NaV1.4).
1 Missense
mutations with gain-of-function changes (GOF; too much
inward Na+ current) are found in hyperkalemic periodic pa-
ralysis (HyperPP), paramyotonia congenita, and several var-
iants of sodium channel myotonia.2 Leaky channels resulting
from mutations of arginine residues in the voltage sensor
domain cause hypokalemic periodic paralysis (HypoPP)
type 2.3,4 These traits are all dominantly inherited.
Loss-of-function (LOF) mutations of SCN4A are encoun-
tered far less frequently and are associated with recessively
inherited phenotypes. A congenital myasthenic syndrome
with ptosis, bulbar weakness, respiratory diﬃculties, and
prolonged episodes of weakness more typical for periodic
paralysis has been associated with missense mutations of
SCN4A that cause a LOF by markedly enhancing channel
inactivation.5–7 More recently, congenital myopathy with
neonatal hypotonia has been reported in patients with null
mutations in SCN4A.8 A homozygous null is embryonic le-
thal, while compound heterozygous mutations (null allele
plus an LOF allele) result in congenital myopathy with sur-
vival to adulthood. Remarkably, family members with a single
SCN4A null allele are healthy.
In this report, we describe the molecular and clinical con-
sequences of 2 additional LOFmutations, both of which are at
residue p.1460. The index cases presented with congenital
hypotonia, respiratory diﬃculties, and delayed motor mile-
stones plus fatigue and were found to have biallelic mutations,
as either p.R1460Q plus p.R1059X or homozygous p.R1460W.
Expression studies of the p.R1460 mutant channels also
revealed GOF changes that account for the myotonia in some
carriers of p.R1460Q. Moreover, the phenotype for some car-
riers of the p.R1460Q mutation in the primary Finnish family
was complicated by the independent cosegregation of a known
CLCN1mutation p.R894X associated with recessive myotonia
congenita.
Methods
Clinical examination
The proband (III-3) and 6 of her relatives were examined in
a Finnish family (F1, ﬁgure 1A). In addition, one of her aunts
(II-6) and hermaternal grandfather (I-1) had similar symptoms
(larynx spasms) but were not available for further studies.
The patients underwent neurologic examination, EMG, and
DNA extraction. Further, a single unrelated Finnish patient
(P2) with myotonia was similarly examined. Muscle histology
was available for 2 patients and muscle MRI for 1 patient. The
proband from family 2 and her parents were examined neu-
rologically and whole blood was collected for DNA analysis.
Clinical electrophysiology
Standard neurography and EMG investigation was performed
in 9 patients with p.R1460Q mutation. Compound muscle
action potential (CMAP) exercise test was carried out in 3
patients. A Fournier protocol was used with short (10–12
seconds) and long (5 minutes) exercise test.9,10 CMAPs were
evoked by supramaximal nerve stimulation. The proband of
family 1 also underwent repetitive nerve stimulation at 30 Hz
and single-ﬁber jitter examinations. The proband of family 2
was studied by needle EMG and repetitive nerve stimulation at
3 Hz and 50 Hz. Because cooperation was limited in a 6-year-
old patient, she did not complete a CMAP exercise test.
Molecular genetics
The DNA of the proband in family 1 was studied by whole
exome sequencing. The DNA sample was used for enrichment
of a sequencing library by NimbleGen SeqCap EZ Human
Exome v2.0 (Roche, Basel, Switzerland). The captured library
was sequenced using an Illumina (San Diego, CA) HiSeq 2000
Sequencer. Sequence reads were aligned to the human refer-
ence genome (UCSC hg19) using the Burrows-Wheeler
Aligner.11 Variant calling was made with Genome Analysis
Toolkit.12 The data were visualized with the Integrative
Genomics Viewer (Broad Institute, Cambridge, MA). DNA
capture, enrichment, next-generation sequencing, and data
analysis were performed at the Institute for Molecular Medi-
cine Finland. From the sequencing data we selected to further
analyze all the exons and exon–intron borders of the following
genes: MTM1, RYR1, DNM2, SEPN1, and SCN4A. For the
other members of family 1, the sequencing of relevant exons of
SCN4A and CLCN1 genes was performed using traditional
Sanger sequencing (table). For some of the patients, 3 com-
mon Finnish mutations in the CLCN1 gene (c.1238T>G
p.F413C, c.1592C>T p.A531V, and c.2680C>T p.R894X)
were studied by targeted mutation detection using TaqMan
Sequence Detection System (ABI Prism 7000, Applied Bio-
systems, Foster City, CA). TaqMan Sequence Detection Sys-
tem is based on ﬂuorescent oligonucleotide probes for both
mutation and normal sequences. The studied fragments were
ampliﬁed by PCR using forward and reverse primers.
Sequences of the primers and probes are available upon re-
quest. DNA of patient P2 was sequenced using MYOcap tar-
geted gene panel.13 Whole exome sequencing was performed
for the proband in family 2 and her parents using the Agilent
(Santa Clara, CA) SureSelect capture kit and an Illumina
HiSeq2500 next-generation sequencer. Analysis of variants was
performed by the UCLA Clinical Genomics Center.
Glossary
CMAP = compound muscle action potential; CMS = congenital myasthenic syndrome; GOF = gain-of-function; HyperPP =
hyperkalemic periodic paralysis; HypoPP = hypokalemic periodic paralysis; LOF = loss-of-function; WT = wild-type.
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Functional assessment of mutant
sodium channels
Sodium channels were transiently expressed in ﬁbroblasts
(HEK cells) as previously described,14 except transfection was
performed with lipofectamine. Cells expressed the human
wild-type NaV1.4 pore-forming α subunit (WT), or mutant
constructs encoding R1460Q or R1460W, plus the β1 acces-
sory subunit. Sodium currents were recorded using the whole
cell voltage-clamp conﬁguration. The electrode contained the
following, in mM: 100 CsF, 35 NaCl, 5 EGTA, 10HEPES, pH
to 7.3 with CsOH; the bath solution contained the following,
in mM: 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 2.5 glucose, 10
HEPES, pH to 7.3 with NaOH. After whole-cell access was
achieved, cells were allowed to equilibrate for 5 to 10 minutes
before recording. For the dataset to determine the voltage
dependence of gating, cells with maximal peak Na+ currents
<1 nA were excluded to minimize the contribution from en-
dogenous Na+ currents (typically <0.1 nA), and those with
peak current >5 nA were excluded tominimize series resistance
errors. To reduce the selection bias for the current density
measurements (ﬁgure 2), cells with peak Na+ currents from
0.5 nA to 10 nA were included. For the experiments to test
for gating pore currents, channels were expressed in Xenopus
oocytes, and currents were recorded using 2-electrode voltage
clamp as previously described.8 The bath solution contained
the following, in mM: 60 Na+-methansulfonate, 60 guanidine
sulfate, 1.8 CaSO4, 10 HEPES, plus 1 μm tetrodotoxin to block
sodium currents conducted by the central core.
The functional properties of WT and mutant sodium channels
were compared quantitatively by obtaining parameter estimates
to functions describing the voltage-dependent changes of the
ionic currents. Channel activation was quantiﬁed by ﬁtting the
peak amplitude (Ipeak) to a linear conductance (Gmax) with
a reversal potential (Erev) that was scaled with a Boltzmann
function: Ipeak = GmaxðV − ErevÞ=ð1 + e−ðV− V1/2Þ/KÞ. The
voltage-dependence for activation of the channel is character-
ized by V1=2, the voltage at which half the channels are acti-
vated, and K, a steepness factor. The relative conductance
(ﬁgure 2C) was calculated as Ipeak divided by GmaxðV − ErevÞ.
The time constant for entry to inactivation was estimated
from a single exponential ﬁt of the current decay (fast in-
activation) or of the change in peak current after pro-
gressively longer conditioning pulses (closed-state inactivation).
Figure 1 Sodium channel mutations
(A) Segregation of clinical phenotype and ge-
notype among 7 carriers of p.R1460Q in family
1 from Finland. (B) Location of p.R1460 in the
pore-forming subunit (NaV1.4) along with
established sites for sodium channelopathies
of skeletal muscle. CMS = congenital myas-
thenic syndrome; HyperPP = hyperkalemic
periodic paralysis; HypoPP = hypokalemic pe-
riodic paralysis; PAM = paramyotonia con-
genita; SCM = sodium channel myotonia.
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Table Phenotype and genotype of the patients
Patient SCN4Amutations CLCN1mutation Symptoms Electrophysiology Other
F1 II-2 c.4379 G>A p.R1460Q/
− (ex 24a)
−/−a Myotonia, larynx spasms Myotonic discharges
F1 II-3 c.4379 G>A p.R1460Q/
− (ex 17, 21, 22, 24a)
c.2680C>T p.R894X/−
(ex 2, 11, 15, 23)
Stiffness, larynx spasms, exercise-induced muscle weakness Myotonic discharge; decrease of CMAP amplitude
after long exercise test
F1 II-4 c.3175C>T p.R1059X/−
(ex 17)
−/− (ex 2, 11, 15, 23) Possibly mild ptosis ND
F1 II-5 c.4379G>A p.R1460Q/
− (ex 24a)
c.2680C>T p.R894X/−
(ex 2, 11, 15, 23)
Exercise-induced myalgia, stiffness, cramps; cold-induced myotonia
in hands
Myotonic discharges
F1 II-7 c.4379G>A p.R1460Q/
− (ex 21, 22, 24a)
−/− (ex 2, 11, 15, 23) Cold-induced myotonia, periodic paralysis during adolescence Increased insertional activity
F1 III-1 c.4379G>A p.R1460Q/
− (ex 22, 24a)
−/−a (ex 2) Myotonia Myotonic discharges
F1 III-2 c.4379G>A p.R1460Q/
− (ex 21, 22, 24a)
−/− (ex 2, 11, 15, 23) Exercise-induced myalgia, stiffness, cramps, larynx spasms Increased insertional activity; normal findings in
CMAP exercise test
Normal muscle MRI; muscle
biopsy: mild abnormalities
F1 III-3 c.4379G>A p.R1460Q/
c.3175C>T p.R1059Xb
c.2680C>T p.R894X/−b
(ex 2)
Congenital hypotonia, motor milestones delayed, mild fixed ptosis,
larynx spasms, muscle fatigue; ambulant, stable during adulthood
Myotonic discharges; 40% decrease of CMAP
amplitude after long exercise test; single fiber:
myasthenic
Muscle biopsy: myopathy
P2 II-1 c.4379G>A p.R1460Q/
−c
−/−c Myalgia, stiffness, cramps Myotonic discharges Targeted gene panel: no
other pathogenic mutations
F2 II-1 c.4378C>T p.R1460W/
c.4378C>T p.R1460W
−/− Congenital hypotonia, gastrostomy and intubation at infancy, motor
delay, respiratory distress
No myotonic discharges; repetitive stimulation no
decrement (3 Hz) or increment (50 Hz)
Parents are carriers and
asymptomatic
Abbreviations: CMAP = compound muscle action potentials; ex = exons studied; n.d. = not done.
a Three common mutations in CLCN1 gene in Finland were studied by targeted mutation detection using TaqMan Sequence Detection System.
b Studied using whole exome sequencing.
c Myocap gene panel, ref 13.
Exons of SCN4A and CLCN1 genes were studied by Sanger sequencing, unless otherwise indicated. Exon 24 of SCN4A was sequenced only partly, which is indicated by marking “24a.”
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Steady-state fast inactivation was quantiﬁed by ﬁtting the
relative peak current at −10 mV after a 300 ms conditioning
pulse (Vcond) to a Boltzmann function IpeakðVcondÞ=Ipeak max =
1=ð1 + eðVcond−V1/2Þ/KÞ. For slow inactivation, a conditioning
depolarization was used to induce inactivation, then a re-
covery pulse at −120 mV for 20 ms was applied to remove fast
inactivation, and ﬁnally the available current (i.e., not slow-
inactivated) was measured for a test pulse to −10 mV. For the
steady-state voltage dependence, a plateau term (S0) was in-
cluded because slow inactivation does not reduce channel
availability to 0 at strongly depolarized potentials. Estimated
values for parameters are presented as mean ± SEM. Error
bars in all graphs show ± SEM.
Data availability statement
Photomicrographs of the muscle biopsy from the proband in
family 1 are available upon reasonable request. The expression
plasmids for the functional studies of mutant sodium channels
are available upon request from the corresponding author.
Standard protocol approvals, registrations,
and patient consents
Informed written consent for genetic testing was obtained
from patients or their guardians. Oocytes were harvested from
adult female Xenopus laevis in accordance with the UK Animal
(Scientiﬁc Procedures) Act 1986.
Results
Clinical presentation and assessment
Family 1
The proband (III-3), a 30-year-old woman, had congenital
hypotonia that was severe at birth, causing diﬃculties in
breathing and feeding, but resolved to milder nonprogressive
muscle weakness and fatigue during the ﬁrst years of life. The
most severe symptoms resolved quickly in the ﬁrst weeks of
life; therefore, she did not need ventilator support or tube
feeding. Motor milestones were delayed; independent sitting
was achieved at 12 months but she started to walk at 18
months of age. From the start, she had severe weakness in the
neck and facial muscles, mild dysphonia, and ﬁxed ptosis bi-
laterally. Otherwise, muscle strength was 4/5 on the Medical
Research Council Scale in all limbs. She had marked fatiga-
bility when climbing stairs; otherwise there was no large
variability in her muscle strength. At age 30 years, she was
ambulant, and could walk on toes but not on heels. Clinical
myotonia was not detected.
Muscle biopsy showed myopathic changes with ﬁber size
variation, increased internal nuclei, structural abnormalities,
and necklace ﬁbers. Some non-rimmed vacuolated ﬁbers were
seen. Several EMG studies were performed and one showed
Figure 2 Sodium current density was reduced for cells transfected with R1460 mutant constructs, but the voltage de-
pendence of activation was not altered
(A) Traces show sodium currents elicited by depolarization from −120mV to test potentials between −75 and +60mV. Note the higher gain for the scale bars in
the mutant channel traces. (B) Peak current density is shown as a function of test potential and displays a marked reduction in current amplitude for both
mutants. (C) The voltage dependence of channel activation, as shown by relative conductance, was indistinguishable between the wild-type (WT) andmutant
channels. Black squares, blue triangles, and red circles correspond to WT (n = 16), R1460Q (n = 12), and R1460W (n = 16), respectively.
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deﬁnite myotonic discharges. Single ﬁber test was myasthenic
with increased jitter and the long-exercise test showed 40%
decrease of CMAP amplitude. The proband had 2 mutations
in the SCN4A gene: 1 missense p.R1460Q inherited from the
mother and a nonsense p.R1059X inherited from the father.
In addition, she had inherited a heterozygous CLCN1 mutation
p.R894X from her mother (ﬁgure 1). Whole exome sequencing
did not reveal any other variants thatmight complicate the results.
Genes associated with channelopathies (SCN4A, CACNA1S,
KCNJ2, CLCN1) or congenital myasthenic syndrome and re-
lated disorders (CHRNA1, CHRNB1, CHRND, CHRNE,
RAPSN, CHAT, MUSK, COLQ, DOK7, AGRN, GFPT1,
DPAGT1, LAMB2, CHRNG, PLEC) were speciﬁcally checked.
The proband’s mother, 3 siblings of the mother, and 2 cousins
were identiﬁed with the p.R1460Q mutation. In addition, one
unrelated patient (P2) carried the same mutation. They all
had myotonic muscle symptoms and signs starting during
young adulthood that either showed myotonic discharges or
increased insertional activity on EMG and clinical myotonia,
or related to muscle stiﬀness, exercise-induced myalgia, and
cramps (table). Most of the p.R1460Q carrying patients in
family 1 had larynx spasms that were evident in cold weather
or at night. TheCLCN1 p.R894Xmutation was also identiﬁed
in the mother and one of her siblings. They had myotonic
discharges on EMG but that was also seen in other siblings
without CLCN1 mutation. The father who carried the non-
sense SCN4A mutation found in the proband possibly had
mild ﬁxed ptosis but was otherwise healthy.
Family 2
The proband was born with hypotonia. She exhibited poor
feeding and respiratory insuﬃciency, requiring gastrostomy as
well as intubation and mechanical ventilation. She was hospi-
talized for the ﬁrst month of life. Motor milestones were
attained including standing and walking, albeit delayed, and the
parents reported day-to-day variability in strength and re-
current breathing diﬃculty. Around 6 years of age, she de-
veloped worseningmotor function and intermittent respiratory
distress, and was referred to the UCLA Neuromuscular Clinic
for further evaluation. Her examination at that time demon-
strated signiﬁcant weakness of axial and appendicular muscles.
She was not able to stand or support her head while in a seated
positon. Reﬂexes were present, although mildly diminished.
Repetitive stimulation of the median and accessory nerves at 3
Hz did not demonstrate a decrement in CMAP amplitude, and
50 Hz repetitive nerve stimulation of the median nerve did not
elicit signiﬁcant increment. No myotonic discharges were
detected by needle EMG. Motor performance varied sponta-
neously, and on subsequent visits over the next 18 months she
was able to stand and walk independently. She did not require
bilevel positive airway pressure at night or other chronic ven-
tilatory support. The patient’s mother reported improvement
of strength and breathing with inhaled albuterol, but the beneﬁt
was not sustained on oral therapy. A trial of pyridostigmine did
not improve strength, but the family reported improved mo-
bility when acetazolamide and albuterol were tried separately.
The parents have no motor symptoms. An older sister re-
portedly had bulbar weakness, was never able to sit without
support, and died at age 1 year from respiratory complications.
The proband is homozygous for c.4378C>T p.R1460W in
SCN4A, and both parents are asymptomatic carriers although
there is no history of consanguinity in the family.
Molecular results
The NaV1.4 variants in these families cause missense sub-
stitutions at the same amino acid, arginine 1,460, which is in
the highly conserved S4 transmembrane segment in domain
IV of the sodium channel (ﬁgure 1B). The allele frequency for
p.R1460W in the gnomAD database is 6 per 276,796, and the
p.R1460Q allele has not been reported. The S4 segments in
the voltage sensors contain positively charged basic amino
acids (arginine or lysine) at every third residue,15 and R1460
is the ﬁfth of 8 such residues in S4 of domain IV. Although
mutation at R1460 in NaV1.4 has not previously been
reported in neuromuscular disorders, all 3 SCN4A mutations
associated with a congenital myasthenic syndrome, and for
which myopathy with ﬂuctuating weakness is a prominent
feature, are missense mutations of the voltage sensor in do-
main IV, and 2 are at other arginines in the S4 segment
(p.R1454W and p.R1457H).5–7 All 3 previously reported
mutations are also unusual because they cause LOF changes
for the sodium channel and recessive inheritance of the syn-
drome, whereas GOF changes are found in SCN4Amutations
associated with myotonia, paramyotonia, or HyperPP.1 We
therefore tested the functional consequences of p.R1460Q
and p.R1460W by recording sodium currents for channels
heterologously expressed in ﬁbroblasts or Xenopus oocytes.
Functional characterization of R1460 mutant
sodium channels
R1460 mutant sodium channels were expressed in the
plasma membrane, but current density was reduced
Sodium currents were detected in HEK cells transfected with
WT as well as R1460W and R1460Q mutant channels (ﬁgure
2). Peak current amplitudes were smaller, however, for cells
expressing mutant channels. The peak current density (pA/
pF to normalize for variations in cell size, ﬁgure 2B) for cells
expressing mutant channels was about 30%–50% that of WT.
At a test potential of – 5 mV, where the sodium current is
largest, the amplitude was statistically smaller for each mutant
compared to WT (p < 0.01, analysis of variance) but the
diﬀerence between the 2 mutants was not distinguishable
(R1460W −73.8 ± 11 pA/pF [n = 9], R1460Q −140 ± 26 pA/
pF [n = 7], WT −278 ± 46 pA/pF [n = 12]).
Channel activation was not altered by R1460Q
or R1460W
The voltage dependence of sodium channel activation is
shown in ﬁgure 1C, where the relative conductance is plotted
as a function of the test potential (see Methods). The data
are completely overlapping between WT and R1460 mutant
channels. Quantitatively, there was no detectable diﬀerence in
the voltage midpoint of activation with V1/2 of WT, R1460Q,
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and R1460W being −18.7 ± 1.1 mV (n = 16), −17.6 ± 1.7 mV
(n = 12), and −19.0 ± 1.4 mV (n = 16), respectively. In
addition, the steepness of the voltage dependence was similar
for all 3: WT, R1460Q, and R1460W being 7.7 ± 0.22 mV, 9.1
± 0.34 mV, and 9.2 ± 0.23 mV, respectively.
Fast inactivation had mixed, LOF, and GOF defects for
R1460 mutant channels
Sodium channels undergo 2 forms of inactivation; fast in-
activation on a time scale of milliseconds, which contributes to
termination of the action potential and limits repetitive ﬁring,
and slow inactivation over a time course of tens of seconds
to minutes. To test the steady-state voltage dependence
of fast invitation (also referred to as availability), we mea-
sured the peak current elicited at −10 mV, after a 300 ms
conditioning pulse to potentials over a range from −130 to
−40 mV (ﬁgure 3A). Depolarization promotes inactivation
(reduces availability), and the voltage dependence was
markedly left-shifted for R1460 mutant channels (V1/2
value for R1460Q −78.1 ± 0.67 mV, n = 10; R1460W −86.1
± 1.5 mV, n = 12; and WT −70.5 ± 0.91 mV, n = 15). In
addition, the steepness of the voltage dependence of
steady-state invitation was reduced for R1460 mutant
channels (k value for WT 5.5 ± 0.88 mV, R1460Q 8.6 ± 0.2
mV, R1460W 7.7 ± 0.2 mV). Combined, these changes in
the voltage dependence of steady-state fast inactivation
produce a substantial LOF, as can be seen by the reduced
availability (ﬁgure 3A) of mutant channels (R1460Q = 0.7,
R1460W = 0.5, compared to WT = 0.9) at the resting po-
tential of −85 mV for skeletal muscle.
Figure 3 Fast inactivation of R1460 mutant channels had both gain-of-function and loss-of-function defects
(A) The steady-state voltage dependence of fast inactivationwas shifted leftward (hyperpolarized) for bothR1460mutant channels relative towild-type (WT). Inset
shows the voltage protocol used tomeasure inactivation produced by a 300ms conditioning pulse at variouspotentials. (B) The rateof inactivationwas slower for
R1460 mutant channels at depolarized potentials, as shown by the superposition of amplitude normalized currents elicited at 10 mV. (C) Recovery from fast
inactivationwas faster for bothR1460QandR1460W, compared toWTchannels (tau recovery of 4.7± 0.6ms,p< 0.0001 [n= 5]; 6.4 ± 0.6ms,p< 0.0001 [n= 7]; 16.8
± 0.4 ms [n = 4], respectively). Data show the time course for the recovery of peak current amplitude at a holding potential of −80 mV, after channels were
inactivatedwitha conditioningpulseof 30msat−10mV (inset). (D) Plot summarizing the voltage-dependent kinetics for entry toor recovery from fast inactivation.
Three separate protocols were used to measure inactivation kinetics, over the entire voltage range (see text, Results). Overall, the changes in steady-state fast
inactivation (A) are loss of function, whereas the slower entry and more rapid recovery from fast inactivation are gain-of-function changes.
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The voltage-dependent kinetics of fast inactivation were
assessed for both entry to and recovery from inactivation. The
entry rate was slower for R1460 mutant channels, which can be
observed directly as a prolonged decay in a superposition of
sodium currents elicited by a step depolarization to 10 mV
(ﬁgure 3B). This slower entry rate was observed over a range of
test potentials (−20 to +60 mV), as shown by the larger am-
plitude time constant of the current decay (ﬁgure 3D). Re-
covery from fast inactivation was recorded using a 2-pulse
protocol. Channels were fast inactivated using a 30 ms condi-
tioning pulse to −10mV, then after a variable duration recovery
at a hyperpolarized potential (−80 to −130 mV), a test pulse to
−10 mV was delivered to determine the relative amplitude of
the peak sodium current (ﬁgure 3C, inset). The time course of
recovery at −80 mV is shown in ﬁgure 3C, and demonstrates
the faster recovery (left shift) for R1460 mutant channels. A
faster recovery rate (smaller time constant) of R1460 mutant
channels was observed over a potential range from −50 to −130
mV (ﬁgure 3D). Finally, the kinetics of closed-state fast in-
activation (ﬁgure 3D, −40 to −70mV) was measured using
a 2-pulse protocol with a 30 ms conditioning pulse to induce
inactivation, followed by a test pulse at −10 mV to measure
the relative current. The altered entry and recovery kinetics for
fast inactivation of R1460 mutants both contribute to a GOF
change, in other words more inward sodium current. In the
physiologic context of an action potential, mutant channels
are predicted to inactivate more slowly at the peak of de-
polarization and then recover more quickly when the mem-
brane potential returns to its resting value (−85 mV).
The impact of the altered kinetics of fast inactivation can be
observed directly by measuring the peak amplitudes of so-
dium currents elicited by a train of brief depolarizing pulses.
Normally, sodium channels do not have time to fully recover
in the interval between action potentials with high-frequency
discharges. We simulated this scenario by measuring sodium
channel availability as the relative peak current elicited by
a 2 ms depolarization to 10 mV, with an intervening recov-
ery interval at −80 mV, over a range of pulse frequencies
(ﬁgure 4). Use-dependent inactivation was pronounced for
WT channels (e.g., 30% decrease at 60 Hz and 50% decrease
at 100 Hz), but was substantially less for R1460 mutant
channels. These data demonstrate a GOF for R1460 mutant
channels that would manifest, for example, as myotonic
bursts.
Slow inactivation was unaffected for both
R1460Q and R1460W mutant channels
Prolonged depolarizations lasting seconds or sustained bursts
of discharges both cause sodium channels to become slow
inactivated, and derangements of slow inactivation are known
to cause susceptibility to periodic paralysis16 or congenital
myasthenia.6 We characterized slow inactivation by using
prolonged step depolarizations (up to 60 seconds) to induce
slow inactivation, followed by a 20ms recovery period at −120
mV to remove fast inactivation, and then applied a test pulse
to −10 mV to detect the presence of slow inactivation as
a reduced peak current. The time course of entry to slow
inactivation at −10 mV was indistinguishable between WT
and R1460 mutant channels (ﬁgure 5A). Similarly, the rate of
recovery was comparable for WT and R1460 mutant channels
at −100 mV (ﬁgure 5B). The small rightward shift represents
about a 1.5-fold slower rate of recovery for R1460 mutants,
although the ﬁtted time constants were not statistically dis-
tinguishable from those of WT channels. The voltage de-
pendence of steady-state slow inactivation, as determined by
30-second conditioning pulses, was identical for WT and
R1460 mutant channels (ﬁgure 5C).
Figure 4 The use-dependent reduction in sodium current peak amplitude was less pronounced in R1460 mutants than in
wild-type (WT) channels
Data show relative peak sodium current elicited by 2 ms depolarizing pulses to 10 mV applied at 60 Hz (A) or 100 Hz (B), from a holding potential of −80 mV.
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R1460 mutant channels do not conduct
a gating pore leakage current
Missense mutations at arginine residues in the S4 segments of
the voltage sensor domains of sodium or calcium channels
account for almost all cases of HypoPP,3 and have a common
functional defect, the gating pore leakage current, caused by
a mutation-induced anomalous ion conduction pathway.4
Since R1460 is an arginine in the S4 segment of domain IV in
NaV1.4 (ﬁgure 1B), we tested whether R1460Q or R1460W
mutant channels have a detectable gating pore leakage cur-
rent. Channels were studied in Xenopus oocytes to achieve
high expression levels suﬃcient to observe gating pore cur-
rents when the main pore was blocked by tetrodotoxin.
Currents recorded from oocytes expressing R1460Q or
R1460W channels were no diﬀerent from WT (ﬁgure 6), as
compared to the positive control with the HypoPP mutation
R1132Q, for which a large gating pore current was detected
(inward current a negative potentials).
Discussion
This report identiﬁes a new residue in NaV1.4 (R1460) where
missense mutations were identiﬁed in patients with recessive
myasthenic congenital myopathy. The clinical manifestations
overlap considerably with prior reports of a recessive congenital
myasthenia syndrome plus periodic paralysis that is associated
with LOF mutations in SCN4A.5–7 The consistent features are
hypotonia at birth, respiratory distress, and feeding diﬃculties
often requiring tube feeds. Motor function at infancy and early
childhood is notable for delayed milestone attainments, ﬁxed
ptosis, myopathic weakness especially of the face and neck,
episodes of hypoventilation, myalgia, and fatigability.
Figure 5 Slow inactivation was not altered by either
R1460W or R1460Q
(A) Onset of slow inactivation showed identical kinetics betweenwild-type (WT)
and mutant channels. Inset shows the voltage protocol to characterize the
onset of slow inactivation by stepping to −10 mV for a variable duration (entry
time), and then measuring the decline in relative loss current that fails to re-
cover within 20 ms at −120mV. (B) The rate of recovery from slow inactivation
wascomparablebetweenWTandR1460mutant channels. Channelswere slow
inactivated by a 30-second step to −10 mV (inset), and the data show recovery
as the relative increase in current after repolarizing to −80 mV for a variable
duration (recovery time). (C) The voltage dependence of steady-state slow in-
activation was indistinguishable between WT and R1460 mutant channels.
Thirty-second conditioning pulses to various conditioning potentials (inset)
wereused todetermine thevoltagedependenceof inactivation. Smooth curves
show best fits to the data with V1/2 of −59.1 ± 1.9mV for WT, −60.9 ± 2.8mV for
R1460Q, and −63.4 ± 2.6 mV for R1460W. The number of cells for the mean
values shown in the data was 5–8 for WT and both R1460 mutant channels.
Figure 6 The R1460 mutations did not cause a gating pore
leakage current
The steady-state current (without subtraction of the nonspecific leak)
recorded from oocytes expressing high levels of wild-type (WT) or R1460
mutant channels is plotted as a function of the membrane potential. Te-
trodotoxin was added to block sodium currents through themain pore. The
I–V relation was identical for WT and R1460 mutant channels, while the
positive control for the p.R1132Q mutation in hypokalemic periodic paral-
ysis showed a gating pore leakage current (large negative current for
membrane potentials more negative than −80 mV). Data are from 6 to 8
oocytes per construct.
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Electrophysiologic signs of myasthenia are variable. The ﬁrst
published report (p.S246L/p.V1442E) was notable for pro-
nounced CMAP decrement during repetitive nerve stimula-
tion (at 2 Hz after a 10 Hz load and at all frequencies of 10 Hz
or higher).5 For the 2 subsequent single-case reports of
SCN4A-associated congenital myasthenic syndrome (CMS),
one had increased jitter7 (as observed for patient F1 III-3
herein) but neither had a CMAP decrement with repetitive
stimulation. Conversely, in the series of 6 families with con-
genital myopathy associated with SCN4A recessive mutations,
1 of 4 available surviving patients had a 60% CMAP decre-
ment with 10 Hz stimulation.8
A consistent pattern is emerging for the genotype–phenotype
associations with LOF mutations in SCN4A. A single mutant
allele, whether a partial loss or complete null, is asymptomatic,
although a mouse model revealed a latent susceptibility to
myasthenia.17 A biallelic deﬁcit with homozygous LOF muta-
tions leads to moderate congenital myopathy with fatigue and
variable electrodiagnostic signs of myasthenia. Compound
heterozygous mutations with a null plus a LOF defect cause
moderate to severe congenital myopathy, including an in-
creased risk of infant mortality. Finally, biallelic null mutations,
whether from nonsense mutations or missense mutations with
no detectable sodium current, are lethal in utero or at birth.8
In hindsight, this paradigm suggests the original report of
SCN4A-associated CMS was indeed caused by a recessive
compound heterozygote (p.S246L/p.V1442E).5 Because the
fast-inactivation defect for p.V1442E was much greater (−33
mV shift) than for p.S246L (−7.3 mV), we initially considered
p.S246L to possibly be a benign polymorphism. In retrospect,
the substantial enhancement of slow inactivation for p.S246L
(−20 mV shift) will reduce NaV1.4 availability at Vrest by
;30%. Recognizing now that a single LOF allele is asymp-
tomatic and that p.S246L does not appear in the gnomAD
database strongly supports the notion that S246L is a func-
tionally relevant LOF mutation.
The clinical phenotypes associated with mutations at p.R1460
described herein were more varied, which we attribute to the
mixed LOF and GOF changes observed for both R1460Q and
R1460W mutant channels. In the primary Finnish family,
inheritance of myasthenic congenital myopathy was recessive
(p.R1460Q/p.R1059X) but myotonia was a partially domi-
nant trait. Latent myotonia was detected by needle EMG in
p.R1460Q carriers, and some had symptomatic myotonia,
especially with the coincident occurrence of an independently
segregating mutation of the chloride channel gene CLCN1
(p.R894X associated with recessive myotonia congenita).
Combined GOF mutations in SCN4A and LOF mutations in
CLCN1 are known to synergistically aggravate the severity of
myotonia.18,19 The LOF defects for R1460W channels were
more severe than those of R1460Q (smaller amplitude, ﬁgure
2; greater left shift of inactivation, ﬁgure 3), whichmay explain
why the parents shown to be p.R1460W carriers did not
have myotonia. Unusual clinical phenotypes have also been
reported for missense mutations of the second arginine in the
voltage sensor of domain IV (p.R1451L and p.R1451C).20,21
In the heterozygous state, p.R1451L is associated with myo-
tonia aggravated by cold and rare episodes of periodic paral-
ysis typical for paramyotonia congenita, which is consistent
with GOF defects manifest as slower entry and faster recovery
from inactivation. An individual homozygous for p.R1451L
had more frequent and severe episodes of weakness, one of
which with serum K+ 2.8 mM was suggestive of HypoPP.21
Expression studies of R1451L did not reveal a gating pore
leakage current—the canonical defect in HypoPP—but in-
stead showed LOF changes (reduced peak current and en-
hanced inactivation) that may cause this unusual form of
periodic paralysis in homozygous patients.21 Unlike the cases
herein, however, the LOF aspects of the mixed channel
defects for p.R1451L did not result in a CMS syndrome in the
homozygous proband.
Our report is the third case of a homozygous recessive
mutation in SCN4A found in CMS/congenital myopathy,
and all 3 missense mutations are at arginine residues in the
S4 segment of the domain IV voltage sensor (p.R1454W6,
p.R1457H7, and p.R1460W). Expression studies for all 3
mutations show a similar pattern of LOF changes with ab-
errant enhancement of inactivation, consistent with the
established structure–function behavior of voltage-gated so-
dium channels; the domain IV sensor is coupled to in-
activation22 whereas domains I–III control activation. All 11
mutations of NaV1.4 that cause HypoPP type 2 are also
missense substitutions of arginines in S4 segments within
voltage sensors.1,3 These mutations all create anomalous
“gating pore” leakage currents that are mechanistically impli-
cated in episodic attacks of depolarization and weakness in
HypoPP.4 The HypoPP mutations of S4 are in domains I–III,
whereas a homologous mutation in domain IV (p.R1448C)
causes paramyotonia congenita and does not create a gating
pore leak.23 Scanning mutagenesis studies have shown that
a missense substitution of any single arginine in S4/DIV is
insuﬃcient to create a gating pore leak,24 and we have con-
ﬁrmed herein that the p.R1460 mutations found in recessive
congenital myopathy do not produce a leak (ﬁgure 6).
Further investigations are required to understand the mech-
anism for the fatigue in CMS/congenital myopathy caused by
mutations in SCN4A. Prolonged episodes of weakness remi-
niscent of periodic paralysis are not likely to be caused by
sustained ﬁber depolarization, as with attacks of HyperPP or
HypoPP, because this clinical symptom occurs with CMS
mutations that lack GOF changes (e.g., p.R1454W6). Fatigue
in this recessive phenotype is more likely to be a consequence
of impaired generation and conduction of action potentials
caused by a marginal sodium current density that may be
exacerbated by use-dependent trapping of sodium channels in
an inactive state.
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